LCS
ADPT icon

Levin Capital Strategies’s Adaptive Biotechnologies ADPT Stock Holding History

Levin Capital Strategies’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-8,000
Closed -$272K – 338
2021
Q3 		$272K Hold
8,000
– – 0.03% 241
2021
Q2 		$327K Buy
+8,000
New +$311K 0.03% 215

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Levin Capital Strategies's ADPT Position: Q4 2021 in Review

Levin Capital Strategies sold out of Adaptive Biotechnologies (ADPT) in Q4 2021, closing a stake of 8,000 shares — an estimated $272K sold.

Levin Capital Strategies first reported a position in ADPT in Q2 2021 and held it in 2 quarters. The position peaked at $327K in Q2 2021. 214 funds tracked by Wall St. Rank hold ADPT as of Q4 2021.

  • Levin Capital Strategies reported no remaining Adaptive Biotechnologies position as of Q4 2021 after selling out during the quarter.
  • Levin Capital Strategies sold 8,000 Adaptive Biotechnologies shares in Q4 2021, an estimated $272K.
  • Levin Capital Strategies first reported a position in Adaptive Biotechnologies in Q2 2021 and held it in 2 quarters.
  • Levin Capital Strategies's Adaptive Biotechnologies position peaked at $327K in Q2 2021.
  • 214 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2021.

Based on Levin Capital Strategies's 13F filing for Q4 2021, filed 15 Feb 2022.